anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a new peptide relating to proctolin, separable from cephalopod animals in purified state and usable as a reagent for the investigation of the information processing mechanism in the nervous system of higher animals and a base compound for the development of agrochemicals and pharmaceuticals. SOLUTION: The objective peptide is expressed by formula I (Xaa is Lys or Arg; Yaa is Met or Leu; and Zaa is Asp or Pro), e.g. the peptide of formula II. The peptide of formula I is separable from cephalopod animals e.g. by extracting the brain of Octopus minor with hot water, adding acetic acid to the extract to a concentration of 3%, centrifugally separating the product after cooling, separating from the obtained crude extract and purifying the product. The peptide of formula I is an intrinsic neuropeptide increasing the pulse rate and constriction extent of the heart of Octopus minor and increasing the spontaneous constriction of the intestines of Octopus minor and Octopus vulgaris.  Accordingly, the peptide is expectable to be applicable for the investigation of the information processing mechanism of the nerve system of higher animals and the development of pharmaceuticals and agrochemicals.
23andMe aims to recruit 91,227 adults to participate in a web-based weight loss intervention. Primary aims include: a.) to confirm whether AG/GG individuals at MTIF3 rs1885988 lose more weight on lifestyle interventions; and b.) to test the performance of a randomized controlled trial vs. self-selection study design in terms of weight loss, drop-outs, and adherence. Secondary (exploratory) analyses will focus on discovery of genetic and non-genetic predictors of weight loss success overall, and examination of potential interactions by intervention type. Web-administered intervention content, videos, and forums will be surfaced to participants every two weeks, and self-reported surveys will be surfaced weekly for the active intervention duration.
RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
Novel 6-deoxyerythromycin derivatives are disclosed, as are methods for their preparation and use as antiinfective agents. The compounds of the invention include 6-deoxyerythromycins and 6-deoxy-15-norerythromycins which are represented by the structural formula (I) in which R1? is selected from OH and H, and R2? and R3? are independently selected from H and CH3?, as well as the pharmaceutically acceptable salts and esters of the above compounds. Additionally disclosed are genetically modified microorganisms which produce the compounds of the invention and means for the preparation of those microorganisms.
Half of patients will be assigned to this group. Quadrants Q1/Q4 will receive ozone administration. Quadrants Q2/Q3 will receive chlorhexidine administration.
The safety and effectiveness of QSYMIA as an adjunct to a reduced-calorie diet and increased physical activity for weight reduction and long-term maintenance of body weight have been established in pediatric patients aged 12 years and older with obesity. Use of QSYMIA for this indication is supported by a 56-week, double-blind, placebo-controlled study in 223 pediatric patients aged 12 years and above, a pharmacokinetic study in pediatric patients, and studies in adults with obesity [see Clinical Pharmacology (12.3)and Clinical Studies (14)] . 

In a pediatric clinical trial, there was one episode of serious suicidal ideation in a QSYMIA-treated patient requiring hospitalization and pharmacologic treatment [see Warnings and Precautions (5.2)] more patients treated with QSYMIA versus placebo reported adverse reactions related to mood (e.g., depression, anxiety) and sleep disorders (e.g., insomnia) [see Warnings and Precautions (5.4). Increases in bone mineral density and linear growth were attenuated in QSYMIA- versus placebo-treated patients [see Warnings and Precautions (5.6)] . Serious adverse reactions seen in pediatric patients using topiramate include acute angle glaucoma, oligohidrosis and hyperthermia, metabolic acidosis, cognitive and neuropsychiatric reactions, hyperammonemia and encephalopathy, and kidney stones. 

The safety and effectiveness of QSYMIA in pediatric patients below the age of 12 years have not been established.
Alcoholism is characterized by the inability of individuals to regulate their consumption of alcohol appropriately. Serotonergic dysfunction has been implicated in the pathophysiology of this illness. Serotonin transporters (SERT) critically regulate the tone of serotonergic transmission (Gobbi et al 2001). In a brain imaging study using the SPECT radioligand, \[123I\] Beta-CIT, male alcoholics who had abstained from alcohol for more than four weeks, had significantly reduced serotonin transporters in the raphe area of the brainstem compared to healthy control subjects (Heinz et al 1998). However, the \[123I\] Beta-CIT ligand, binds with high affinity to both the dopamine transporter (DAT) and SERT. Binding of \[123I\] Beta-CIT in regions rich in SERT or DAT have been attributed to SERT and DAT respectively but in regions of mixed innervation (e.g. cortical regions), it is not possible to distinguish between SERT and DAT.

\[11C\]DASB is a PET ligand with high affinity for SERT with almost 1,000 fold selectivity versus DAT. Using this tracer, we will be able to measure SERT binding in cortical and subcortical brain regions including those with mixed innervation. \[11C\] DASB PET studies in humans (Houle et al 2000; Meyer et al 2001) indicate the feasibility of quantifying SERT binding in SERT rich regions. In the current protocol, we plan to use PET imaging with the radioligand, \[11C\] DASB, for serotonin transporter (SERT) to delineate regional abnormalities in SERT binding in two subject groups consisting of 30 patients with alcoholism and 30 healthy volunteers. Our goal of the present study is to further our understanding of the roles of the serotonergic systems in the pathophysiology of alcoholism.
The invention relates to immunogenic polypeptides, particularly polypeptides comprising an amino acid sequence selected from the group set out in SEQ ID NOs: 1 to 26 of Table 1, or variant of such sequences that incorporate an amino acid sequence that differs from one of SEQ ID NOs: 1 to 26 by alteration of up to 2 amino acid residues within the coronavirus-derived portion of the sequence set out in Table 1. The polypeptides may be linear, or branched, and may be subject to modification, such as by addition of palmitic acid, at the N or C terminal. There are also provided nucleic acid sequences encoding the polypeptides, pharmaceutical compositions comprising such polypeptides or nucleic acid sequences, and cells expressing the polypeptides or comprising the nucleic acid sequences. These agents are useful for the prevention or treatment of coronavirus-based infections, such as COVID-19 caused by SARS-CoV-2. Accordingly, the invention also provided medical uses and methods of treatment directed to the prevention or treatment of such infections. Certain formulations using the polypeptides in combination with adjuvants and/or carriers are demonstrated to offer particular advantages.
Gram-negative sepsis has become a substantial and escalating global healthcare challenge due to the growing antibiotic resistance crisis and the sluggish development of new antibiotics. LL-37, a unique Cathelicidin species found in humans, exhibits a wide range of bioactive properties, including direct bactericidal effects, inflammation regulation, and LPS neutralization. KR-12, the smallest yet potent peptide fragment of LL-37, has been modified to create more effective antimicrobials. In this study, we designed two myristoylated derivatives of KR-12, referred to as Myr-KR-12N and Myr-KR-12C. These derivatives displayed remarkable ability to spontaneously assemble into nanoparticles when mixed with deionized water. Myristoylated KR-12 derivatives exhibited broad-spectrum and intensified bactericidal activity by disrupting bacterial cell membranes. In particular, Myr-KR-12N showed superior capability to rescue mice from lethal E. coli-induced sepsis in comparison with the conventional antibiotic meropenem. We also confirmed that the myristoylated KR-12 nanobiotic possesses significant LPS binding capacity and effectively reduces inflammation in vitro. In an in vivo context, Myr-KR-12N outperformed polymyxin B in rescuing mice from LPS-induced sepsis. Crucially, toxicological assessments revealed that neither Myr-KR-12N nor Myr-KR-12C nanobiotics induced meaningful hemolysis or caused damage to the liver and kidneys. Collectively, our study has yielded an innovative nanobiotic with dual capabilities of bactericidal action and LPS-neutralization, offering substantial promise for advancing the clinical translation of antimicrobial peptides and the development of novel antibiotics. This addresses the critical need for effective solutions to combat Gram-negative sepsis, a pressing global medical challenge.
In the modified barium swallowing study, liquid in the amount of 5 ml was used because it is the optimal amount to monitor physiological events during swallowing . The Penetration Aspiration Scale (PAS) was used to determine the dysphagia severity. The PAS is an 8-point scale describing the degree and nature of laryngeal penetration and aspiration, where a score of 1 refer to 'No penetration or aspiration- No entry of material into the airway', and 8 refer to 'Airway aspiration- Material enters the trachea with no attempt to clear'. According to the MBSS, patients who received a PAS score of 1 were included in the group without dysphagia (control group), and those received a PAS score between 2 and 8 were included in the group with dysphagia (study group).
All patients with chronic periodontitis (age 30 years and older) attending the selected Public Dental clinics in VG are eligible. The patients should have at least 8 teeth with pathological pockets (probing pocket depth ≥5 mm and bleeding on probing). Only patients providing signed informed consent are included.

Reported data in the study by Wennström et al. (J Clin Periodontol 2005) were used for power calculation. Thus, a total sample of 834 patients will provide a power of 95% at a significance level of p\<0.05 to detect a difference of 5% in proportion of sites with "pocket closure" i.e. PPD ≤4 mm and BoP negative (primary efficacy variable) between treatment groups. For a power of 80% a total sample of 506 patients is required.
Active treatment contain 60g of feces from a single healthy, screened donor. The feces is combined with glycerol and saline to a total volume of 440 ml in an enema bag. Each participant will only receive a single treatment at baseline.
This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
The invention relates to a traditional Chinese medicine preparation having effects of nourishing liver and kidney, replenishing qi and blood and nourishing heart and nerves and a preparation technology thereof. The traditional Chinese medicine preparation comprises 80-120 parts of suncured ginseng, 80-120 parts of red ginseng, 180-220 parts of prepared polygonum multiflorum, 180-220 parts of human placenta, 180-220 parts of fruit of Chinese magnoliavine and 100-140 parts of dried orange peel. The preparation method comprises the following steps of crushing human placenta, carrying out sieving to obtain fine human placenta powder, extracting volatile oil of dried orange peel by a steam distillation method, condensing the aqueous liquid to obtain aqueous extract, carrying out ethanol backflow extraction on the suncured ginseng, red ginseng, prepared polygonum multiflorum and fruit of Chinese magnoliavine, concentrating the filtrate to obtain alcohol extract, mixing the alcohol extract, the volatile oil, the aqueous extract and the fine human placenta powder, adding a filler into the mixture, and processing tablets, pills or capsules. The traditional Chinese medicine preparation has substantial effects on fatigue syndromes such as neurasthenia, insomnia and dreaminess, cachexia, dizziness, palpitaition and shortness of breath. The preparation technology has scientific and reasonable processes. The traditional Chinese medicine preparation has definite therapeutic effects and stable and controllable quality and is suitable for industrial production.
A method of preparing the dendritic cell tumor vaccine includes steps as follows. A tumor specimen is primarily isolated and cultured to obtain a plurality of tumor cells. Cancer stem cells having a specific cell surface marker are sorted from the tumor cells. The cancer stem cells are irradiated with a radiation. A plurality of dendritic cells are provided. The dendritic cells and the cancer stem cells irradiated with the radiation are co-cultured for activating the dendritic cells into cancer-stem-cell-antigen-presenting dendritic cells to obtain the dendritic cell tumor vaccine. The dendritic cell tumor vaccine is a mixture of the cancer-stem-cell-antigen-presenting dendritic cells and the cancer stem cells.
Lens cells and proteins are encapsulated, and they are not turned over or replaced.The lens nucleus starts to form before birth, so the nucleus is one of the three oldest tissues in the body .With aging, continuous cardiomyocyte stress derails proteostasis by causing excessive autophagy and protease activation, and, ultimately, contractile and electrophysiological dysfunction. Aggregate deposition, proteostasis deterioration, and diffusion degradation between the nucleus and cortex are the main reasons for lens aging.Heart, lens, and neuronal cells change significantly with age, and they are older than cells from renewable tissues.

Near vision deterioration during aging results from a decrease in accomodation amplitude (AA). Cardiac aging is an independent risk factor for cardiovascular disease. Thus, the investigators investigated the association between cardiac aging and AA. The subjects (500 mean 50-year-old subjects, with equal males and females) were divided into two groups according to AA measured with a Raf ruler. The nucleus diameter change at 1 D accomodation was measured using ImageJ. Cardiac conduction system differences, autonomic aging, myocardial aging were evaluated using electrocardiography, heart rate variability and diastolic dysfunction. For near distance vision,compared to subjects who could see clearly from 24-28 cm, subjects who could see clearly from 29-33 cm had a 2.104-fold higher risk of a lateral e' velocity \<10 cm/s\[95%CI; 1.312-3.374\], 2.603-fold higher risk of diastolic dysfunction\[95%CI; 1.453-4.662\], 1.54-fold higher risk of a low/high frequency ratio \>3.1, \[95%CI;1.085-2.197\]. Subjective AA measurement can predict important heart aging parameters.
PURPOSE:A preventing agent for carious teeth containng at least one compound, e.g. 4-tert-butylcyclohexanol, ethyl-n-amyl ketone, etc. as an active constituent. CONSTITUTION:A preventing agent for a crious tooth prepared by incorporating 0.001-5wt%, preferably 0.1-2wt%, at least one of compounds shown in the table as an active constituent with a composition for the oral cavity. A dentifrice, e.g. toothpaste, troche, mouthwash, solid mouth refrigerant, liqud mouth refrigerant, chewing gum or embrocation, etc. may be cited as the composition for the oral cavity suitable for the incorporation. A dentine reinforcing agent, e.g. sodium monofluorophosphate, a germicide, e.g. chlorohexidine, an anti-inflammatory agent, e.g. dihydrocholesterol, a tissue activator, e.g. hinokitiol, and lysozyme or common salt as the active constituent may be incorporated with the composition.
BACKGROUND: Veterans have unique military risk factors and exposures during deployment that may augment their risk of post-acute sequelae of SARS-CoV-2 (PASC). The purpose of this study is to identify potential risk factors for PASC among Veterans in the national Airborne Hazards and Open Burn Pit Registry (AHOBPR).
METHODS: This prospective observational study consisted of a semi-structured interview conducted via phone or videoconference from November 2021 to December 2022 among a stratified random sample of deployed Veterans nested within the national AHOBPR with laboratory-confirmed SARS-CoV-2 infection. PASC was defined as persistent new-onset symptoms lasting more than 2 months after initial SARS-CoV-2 infection. Deployment history, airborne hazards exposure and symptoms were obtained from the AHOBPR self-assessment questionnaire completed prior to SARS-CoV-2 infection (past). Post-infection symptoms and health behaviors obtained at study interview (present) were used to test the hypothesis that deployment experience and exposure increases the risk for PASC.
RESULTS: From a sample of 212 Veterans, 149 (70%) met criteria for PASC with a mean age of 47 ± 8.7 years; 73 (49%) were women and 76 (51%) were men, and 129 (82.6%) continued to experience persistent symptoms of SARS-CoV-2 (596.8 ± 160.4 days since initial infection). Neither exposure to airborne hazards (OR 0.97, CI 0.92-1.03) or to burn pits (OR 1.00, CI 0.99-1.00) augmented risk for PASC.
CONCLUSIONS: PASC is highly common among Veterans enrolled in the AHOBPR, but we did not observe any unique military risk factors (e.g., airborne hazards exposure) that augmented the risk of PASC. Our findings may provide guidance to clinicians in the VHA network to administer appropriate care for Veterans experiencing PASC.
This study will evaluate the efficacy of a risk avoidance program for middle school students and a theoretically-comparable risk reduction program relative to standard care. The study design is a randomized controlled trial conducted in fifteen inner-city middle schools in Houston, Texas. Five schools were randomly assigned to a risk avoidance intervention, five to a risk reduction intervention, and five to a comparison (standard care) condition. Approximately, 1,800 7th grade students were recruited into the study and will be followed over a three-year period. Based on a formative study, a pilot study, and input from community groups and a national panel of experts, two comparable curricula were developed. The risk avoidance curriculum emphasizes sexual abstinence until marriage and includes the requirements for abstinence education as defined in Title V, Section 510. The risk reduction curriculum emphasizes abstinence and addresses condom and contraceptive use. The risk avoidance and risk reduction interventions each consist of an age-appropriate classroom curriculum and a CD-ROM-based tailored intervention delivered in 7th and 8th grade. Each intervention was delivered by trained facilitators. The effect of the interventions will be evaluated by assessing sexual risk-taking behaviors of participants in each intervention (proportion of students initiating sexual intercourse, proportion that are sexually active, number of times of unprotected sex, number of sexual partners) relative to the comparison group. Risk assessment data from students was collected by using an audio computer-assisted self-interview (ACASI) approach for the collection of baseline, 6-, 18-, and 24-month data. Parental permission and child assent were required prior to participation. In addition, we will conduct a 36-month follow-up survey and a one-time urine-based test for chlamydia, gonorrhea, and trichomonas which will provide additional longitudinal data to assess the impact of each curriculum, relative to standard care.
Disclosed is a clonal strain of acceptably attenuated vaccinia virus. It is isolated from cultured cells in which the New York City Board of Health vaccinia virus strain, ACAM 1000 (ATCC Deposit No. PTA-332 I), or a progeny thereof (æthe strainsÆ) has been cultured. The vaccinia virus is described to be able to induce a protective or therapeutic immune response against variola virus (the causative agent of smallpox) in a human. A method of obtaining a colonal strain of attenuated vaccinia virus for use as a vaccine is also described. The method comprises: (i) propagating the strains, or a progeny thereof in a cell culture system, and (ii) isolating from the cell culture system a clonal strain of vaccinia virus that has substantially the same virulence, immunogenicity, growth characteristics in culture, or restriction endonucleases digestion pattern as the strains. The virulence is determined by a rabbit skin test, or by a sucking mouse neurovirulence test.
Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.
Some burns will heal best with the use of temporary skin grafts from cadavers before covering the burns with grafts of the patient's own skin. This is the usual care for these types of burn injuries recommended by burn surgeons. This skin is applied in the operating room and removed after several days. During that time, the body's immune system will make antibodies to the skin. Normally, these antibodies are harmless. However, extra antibodies can make it difficult to find donors for transplants. The results of this study will be used to better understand how to treat a subset of burn patients with very severe burns in a way that allows them to receive tissue transplants (e.g. face transplants, hand transplants).
Each subject will receive both active (STP705) and control (Placebo) intradermal injection twice a week for a total of 4 weeks at 20 μg/cm2/day (in Cohort A), 30 μg/cm2/day (in Cohort B) and 40 μg/cm2/day (in cohort C). The total length of linear hypertrophic scar will be divided equally for treatment with STP705 and placebo. STP705 and Placebo will be injected intradermal every 1 cm length on the hypertrophic scar.
Recommended Dosage for Treatment of HIV-1:

The recommended dosage of NORVIR is 600 mg twice daily by mouth to be taken with meals. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. NORVIR should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily. The maximum dose of 600 mg twice daily should not be exceeded upon completion of the titration [see Dosage and Administration (2.6)].

Pregnant Women

NORVIR oral solution is not recommended during pregnancy due to its ethanol content. NORVIR oral solution contains the excipients ethanol (approx. 43% v/v) and propylene glycol (approx. 27% w/v)  [see Use in Specific Populations (8.1)].
The patient's primary care provider (PCP) will deliver a 9-minute scripted intervention on credible nutrition and lifestyle information. The control intervention is designed to not be specific enough to change strategies related to asthma control.
This invention discloses the use of non-coding RNA SNHG17 as a biomarker and a therapeutic target that relates to the technical field of tumor biotherapy. This invention discloses a use of the non-coding RNA SNHG17 for the manufacture of a detection agent for predicting the drug resistance of fulvestrant. This invention also discloses the use of shRNA for inhibiting non-coding RNA SNHG17 expression. This shRNA can knockdown the expression of the non-coding RNA SNHG17 efficiently. In this way, the sensitivity of fulvestrant-resistant breast cancer cells can be increased. So this invention has good prospects for drug development.